Kenneth William Sommerville

US Patent:

20020031549, Mar 14, 2002

Filed:

Jun 8, 2001

Appl. No.:

09/877681

Inventors:

Yihong Qiu - Gumee IL, US
J. Bollinger - Libertyville IL, US
Sandeep Dutta - Waukegan IL, US
Howard Cheskin - Glencoe IL, US
Kevin Engh - Kenosha WI, US
Richard Poska - Mundelein IL, US
Kenneth Sommerville - Libertyville IL, US

International Classification:

A61K009/22
A61K031/19

US Classification:

424/468000, 514/557000

Abstract:

A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.

US Patent:

20020025341, Feb 28, 2002

Filed:

Jun 8, 2001

Appl. No.:

09/877682

Inventors:

Yihong Qiu - Gumee IL, US
J. Bollinger - Libertyville IL, US
Sandeep Dutta - Waukegan IL, US
Howard Cheskin - Glencoe IL, US
Kevin Engh - Kenosha WI, US
Richard Poska - Mundelein IL, US
Kenneth Sommerville - Libertyville IL, US

International Classification:

A61K009/22

US Classification:

424/489000, 424/468000

Abstract:

A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.